Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older.

Walter AgenoRenato D LopesMark GoldinRoger D YusenGregory W AlbersGregory C ElliottJonathan L HalperinWilliam R HiattGregory MaynardPhilippe Gabriel StegJeffrey I WeitzEunyoung SuhWentao LuElliot S BarnathanGary E RaskobAlex C Spyropoulos

Published in: Journal of thrombosis and haemostasis : JTH (2021)

Symptomatic VTE and VTE-related death occur frequently in older patients with acute medical illness. The benefit/risk profile of rivaroxaban in patients ≥75 years of age appears consistent with that observed in the general population.

Keyphrases

venous thromboembolism
end stage renal disease
newly diagnosed
healthcare
chronic kidney disease
prognostic factors
physical activity
peritoneal dialysis
patient reported outcomes
direct oral anticoagulants
middle aged